Sensors for Medicine and Science (SMSI) has secured $54m in Series D equity financing to develop and commercialise an implantable, long-term continuous glucose monitoring system, used to treat diabetes.

The system features a miniaturised sensor, which is inserted into the subcutaneous space, and an external display reader.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The move follows a human pilot study, which demonstrated that the system accurately measured glucose.

The financing round was led by Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

SMSI plans to use the funds to advance clinical development programmes and regulatory approvals.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now